Try our Advanced Search for more refined results

July 01, 2019

Skiadas v. Acer Therapeutics Inc. et al

Track this case

Case Number:

1:19-cv-06137

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Gregory H. Woods

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. July 22, 2021

    Drugmaker Acer To Pay $8.35M To End Investor Suit

    Drugmaker Acer Therapeutics Inc. has agreed to pay $8.35 million to end investor claims that it misrepresented conversations it had with the U.S. Food and Drug Administration, which allegedly hurt investors when its share prices fell after the FDA rejected a new drug application the company had submitted.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login